FDA OKs Sparsentan for IgA Nephropathy-Related Proteinuria
(MedPage Today) -- The FDA granted accelerated approval to sparsentan (Filspari) for proteinuria in IgA nephropathy, Travere Therapeutics announced, marking the first non-immunosuppressive therapy for this rare condition.
Also known as Berger...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Primary Care | Proteinuria